CLEVELAND--(BUSINESS WIRE)--Imalux Corporation announced that it has initiated a series of major European clinical trials to help identify the earliest signs of bladder cancer.
A prospective bladder cancer study in smokers, first of its kind, is being conducted under the direction of Prof. Georg Bartsch, Chairman of the Urology Department and Dr. Hannes Steiner of the University of Innsbruck, Austria. The Company’s Niris™ Imaging System uses optical coherence tomography (OCT) and will add high resolution imaging to help in early detection of cancer. This bladder screening program is expected to enroll over 25,000 patients.
